What is the current market size and future outlook for the acute myeloid leukemia market?
The acute myeloid leukemia market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growth aging population, environmental factors, genetic predisposition, limited treatment options, medical advancements.
The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing advancements in targeted therapies, immunotherapies development, precision medicine approaches, increased awareness and early detection, collaborative research initiatives. Major trends in the forecast period include emphasis on minimal residual disease monitoring, integration of artificial intelligence (ai) in treatment decision support, focus on supportive care and quality of life interventions, collaborative research initiatives and clinical trials, patient advocacy and empowerment programs.
Get Your Free Sample of The Global Acute Myeloid Leukemia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6100&type=smp
What are the top drivers to the rising demand in the acute myeloid leukemia market?
The increase in the older population base and growing unmet healthcare needs is expected to propel the growth of the acute myeloid leukemia market over the coming years. The geriatric population and growing unmet healthcare are defined as the elderly population, people aged 65 and over suffering from health issues like acute myeloid leukemia. For instance, according to the American Cancer Society USA (ACS), a nationwide voluntary health organization, in 2022, AML was commonly found in elderly people with an average age at diagnosis being 68, and survival of elderly AML patients remained remarkably low. It affected approximately 60,650 people in 2022 and caused 24000 deaths. Therefore, the geriatric population base and growing unmet healthcare needs drive the gelatin market.
How is the acute myeloid leukemia market segmented?
The acute myeloid leukemia market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy
2) By Chemotherapy: Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy
3) By Regimen: DC Regimen, AVD Regimen, VCD Regimen
4) By End-User: Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics
Subsegments:
1) By Chemotherapy: Induction Chemotherapy, Consolidation Chemotherapy
2) By Radiation Therapy: Total Body Irradiation, Localized Radiation Therapy
3) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
4) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Other Targeted Agents
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report
Who are the top competitors in the acute myeloid leukemia market?
Major companies operating in the acute myeloid leukemia market include Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.
What significant trends should we anticipate in the acute myeloid leukemia market over the forecast period?
Growing investments in R&D using the pharmaceutical groups are a key trend gaining popularity in the acute myeloid leukemia market. R&D is used to develop new and improved products and services to fulfill the needs of drug development. For instance, in May 2022, according to National Library of Medicine, a US-based national medical library, a study with the title ‘Daunorubicin or Idarubicin with Cytarabine Plus Quizartinib vs. Physician’s Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)’ is in Phase III of clinical trials. It commenced in November 2021 and is expected to conclude by March 2025.
Which regional trends are influencing the acute myeloid leukemia market, and which area dominates the industry?
The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
What Does The Acute Myeloid Leukemia Market Report 2025 Offer?
The acute myeloid leukemia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Acute myeloid leukemia (AML) is a type of blood cancer that occurs due to abnormal white blood cell in bone marrow. Myeloblasts, also known as leukemic blasts, or excessive production of immature white blood cells, are the hallmark of AML. The bone marrow is crowded with these cells, which stops it from producing healthy blood cells.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6100
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
